Abstract

Research Article

Electrocardiographic criteria in founder mutations related to Arrhythmogenic cardiomyopathy

Stefan Peters*

Published: 02 February, 2018 | Volume 3 - Issue 1 | Pages: 006-007

Founder mutations are rare causes in arrhythmogenic cardiomyopathy including TMEM43 und phospholamban mutations. The incidence is approximately 1%. P.S358L TMEM43 mutations cause aggressive, in most cases biventricular arrhythmogenic cardiomyopathy [1], with the necessity of primary prophylactic ICD implantation in men and in women>30 years for sudden cardiac death prevention.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001021 Cite this Article Read Full Article PDF

References

  1. Abdel Wahab A, Gardner M, Parkash R, Gray C, Sapp J. Ventricular tachycardia ablation in arrhythmogenic right ventricular cardiomyopathy patients with TMEM43 gene mutations. J Cardiovasc Electrophysiol 2018; 29: 90-97. Ref.: https://goo.gl/479Nom
  2. Milting H, Klauke B, Christensen AH, Müsebeck J, Walhorn V, et al. The TMEM43 Newfoundland mutation p.S358L causing AVRC-5 was imported from Europe and increases the stiffness of the cell nucleus. Eur Heart J 2015; 36: 872-881. Ref.: https://goo.gl/5nuLE3
  3. Van Rijsingen IA, van der Zwaag PA, Groeneweg JA, Nannenberg FA, Jongbloed JD, et al. Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet. 2014; 7: 455-465. Ref.: https://goo.gl/dxya6v
  4. Hodgkinson KA, Connors SP, Merner N, Haywood A, Young TL, et al. The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43. Clin Genet. 2013; 83: 321-331. Ref.: https://goo.gl/ec7JiK
  5. Groeneweg JA, van der Zwaag PA, Olde Nordkamp LR, Bikker H, Jongbloed JD, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy according to revised 2010 task force criteria with inclusion of non-desmosomal phospholamban mutation carriers. Am J Cardiol. 2013; 112: 1197-1206. Ref.: https://goo.gl/xLgKxQ
  6. Zhang L, Liu L, Kowey PR, Fontaine GH. The electrocardiographic manifestations of arrhythmogenic right ventricular dysplasia. Curr Cardiol Rev. 2014; 10: 237-245. Ref.: https://goo.gl/vgyvwm
  7. Peters S. Prognostic value of epsilon waves in lead AVR in arrhythmogenic cardiomyopathy. Int J Cardiol. 2015; 191: 77-78. Ref.: https://goo.gl/7WA3Wm
  8. Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missence mutation in the TMEM43 gene. Am J Hum Genet. 2008; 82: 809-821. Ref.: https://goo.gl/sbrfH2
  9. Sepehrkhony S, Gho JMIH, van Es R, Harakalova M, de Jonge N, et al. Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. Heart Rhythm. 2017; 14: 1024-1032. Ref.: https://goo.gl/MfCGfc
  10. Peters S. Clinical importance of lead aVR in arrhythmogenic cardiomyopathy. Int J Cardiol. 2014; 176: 508-509. Ref.: https://goo.gl/x8788E
  11. Peters S. Low amplitude of inverted T-waves in lead aVR characterise patients with arrhythmogenic cardiomyopathy. Int J Cardiol. 2016; 220: 202. Ref.: https://goo.gl/HLNytQ

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?